STOCK TITAN
  1. Home
  2. Sec-filings
  3. BLTE
  4. [Form 4] BELITE BIO, INC Insider Trading Activity

Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under Rule 10b5-1 plan

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Belite Bio Chief Scientific Officer Nathan L. Mata reported selling a total of 1,000 American depositary shares in open-market transactions. The sales occurred on April 27, 2026 at prices ranging from about $160.83 to $164.07 per share. Following these trades, he directly holds 7,666 American depositary shares, each representing one ordinary share of Belite Bio. The filing notes that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on 12/10/2025, indicating the sales were scheduled in advance rather than timed discretionarily.

Positive

  • None.

Negative

  • None.
Insider MATA NATHAN L.
Role Chief Scientific Officer
Sold 1,000 shs ($163K)
Type Security Shares Price Value
Sale American depositary share 44 $160.8345 $7K
Sale American depositary share 280 $161.6211 $45K
Sale American depositary share 231 $162.3775 $38K
Sale American depositary share 409 $163.5573 $67K
Sale American depositary share 36 $164.0717 $6K
Holdings After Transaction: American depositary share — 8,622 shares (Direct, null)
Footnotes (1)
  1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025. Represents the weighted average price of shares sold at prices that ranged from $160.54 to $160.95. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $161.075 to $161.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $162 to $162.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $163 to $163.995. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price. Represents the weighted average price of shares sold at prices that ranged from $164 to $164.59. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
Shares sold 1,000 American depositary shares Open-market sales on April 27, 2026
Post-transaction holdings 7,666 American depositary shares Directly held after April 27, 2026 sales
Sale price (highest reported) $164.0717 per share One trade block on April 27, 2026
Sale price (lowest reported) $160.8345 per share One trade block on April 27, 2026
Price range in footnotes $160.54–$164.59 per share Detailed weighted-average price ranges across trades
ADS to ordinary share ratio 1 ADS = 1 ordinary share As described in footnote regarding security structure
Trading plan adoption date 12/10/2025 Rule 10b5-1 trading plan for reported sales
American depositary share financial
"Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer."
An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"Represents the weighted average price of shares sold at prices that ranged from $160.54 to $160.95."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"Sale in open market or private transaction"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MATA NATHAN L.
(Last)(First)(Middle)
7708 MARKER ROAD
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Scientific Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/27/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American depositary share(1)04/27/2026S(2)44D$160.8345(3)8,622D
American depositary share(1)04/27/2026S(2)280D$161.6211(4)8,342D
American depositary share(1)04/27/2026S(2)231D$162.3775(5)8,111D
American depositary share(1)04/27/2026S(2)409D$163.5573(6)7,702D
American depositary share(1)04/27/2026S(2)36D$164.0717(7)7,666D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/10/2025.
3. Represents the weighted average price of shares sold at prices that ranged from $160.54 to $160.95. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
4. Represents the weighted average price of shares sold at prices that ranged from $161.075 to $161.99. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
5. Represents the weighted average price of shares sold at prices that ranged from $162 to $162.98. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
6. Represents the weighted average price of shares sold at prices that ranged from $163 to $163.995. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
7. Represents the weighted average price of shares sold at prices that ranged from $164 to $164.59. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.
/s/ Nathan L. Mata04/28/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Belite Bio (BLTE) insider Nathan L. Mata do in this Form 4?

Nathan L. Mata, Chief Scientific Officer of Belite Bio, sold 1,000 American depositary shares in open-market trades. The sales were executed on April 27, 2026 under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025.

How many Belite Bio (BLTE) shares does Nathan L. Mata hold after these sales?

After the reported transactions, Nathan L. Mata directly holds 7,666 American depositary shares of Belite Bio. Each American depositary share represents one ordinary share, so his disclosed direct position equals 7,666 ordinary shares following the April 27, 2026 trades.

At what prices did Belite Bio (BLTE) insider shares trade in this Form 4?

The reported open-market sales occurred at weighted average prices between about $160.83 and $164.07 per American depositary share. Footnotes state narrower price ranges for different trade blocks, with detailed breakdowns available from the reporting person upon request.

Was the Belite Bio (BLTE) insider sale made under a Rule 10b5-1 plan?

Yes. The filing specifies that the sales were effected pursuant to a Rule 10b5-1 trading plan adopted by Nathan L. Mata on 12/10/2025. Such plans pre-schedule trades, reducing the likelihood that timing reflects short-term views on the stock.

What type of security did Belite Bio (BLTE) insider Nathan L. Mata sell?

He sold American depositary shares of Belite Bio. A footnote clarifies that each American depositary share corresponds to one ordinary share of the company, with a par value of US$0.0001 per ordinary share.